Key Insights

Highlights

Treatment Research

4 treatments under study, led by Ryz101

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

2Total
Phase 1/2 (1)
Phase 2 (1)

Trial Status

Terminated1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06590857Phase 1/2Recruiting

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

NCT00461773Phase 2TerminatedPrimary

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Showing all 2 trials

Research Network

Common Treatments

  • Ryz1011
  • Bevacizumab1
  • Letrozole1
  • Standard Of Care Endocrine Therapy1

Active Sponsors

  • Genentech, Inc.1
  • Yale University1
  • RayzeBio, Inc.1
  • Novartis1

Top Investigators

Related Conditions

  • Bone Metastases In Subjects With Advanced Breast Cancer1
  • Estrogen Receptorpositive Breast Cancer1
  • Breast Cancer1
  • Er Breast Cancer1
  • Hormonesensitive Metastatic Breast Cancer1

Activity Timeline